Kornimate/medical-research-clean huggingface dataset:
intradialytic resistance training in haemodialysis patients

Conditions: Chronic Kidney Disease Requiring Chronic Dialysis

Summary: the study will investigate the effects of an intradialytic resistance training on mirna´s expression and muscle strength in haemodialysis patients.

chronic kidney disease (ckd) is accompanied by distortions of immune functions and acceleration of inflammation processes. regular exercise has shown great potential for improving the health-related parameters of ckd patients. moreover, muscle strength is considered to be an important predictor of protein- and energy- wasting, inflammation, quality of life and mortality in ckd patients. the behaviour and individual variability of adaptation to regular, controlled, supervised physical activities in ckd patients are not well defined and understood. the understanding of molecular adaptation mechanisms, represented by the epigenetic impact of exercise on renal specific mirna´s expression, is necessary for future improvements in clinical practice. monitoring pro- and anti-inflammation genes activity, their transcription factors and expression of mirna molecules (influencing the signalling pathways of specific genes) will enable us to draft a new transcription and translation model for exercise-induced adaptation in ckd patients. additionally, our results will indicate the clinical value of selected markers for the diagnostics and prognostics of disease.

Eligibility criteria:
inclusion criteria: * all patients over 30 years of age, diagnosed with chronic kidney disease, treated with haemodialysis are eligible for our study. exclusion criteria: * lower extremity amputation, severe dementia or retardation, acute intercurrent disease and probability of one year mortality higher than 25 % according to charlson comorbidity index (cci) are the exclusion criteria for participation in the study.

Keywords: resistance training circulating mirna muscle strength
pretreatment with unfractionated heparin for st elevation myocardial infarction

Conditions: STEMI - ST Elevation Myocardial Infarction

Summary: rupture of a coronary artery plaque leads to thrombotic occlusion of the coronary artery and would present as st segment elevation myocardial infarction. early treatment with aspirin and early primary percutaneous coronary intervention are indicated. anticoagulation therapy, usually with unfractionated heparin, is required during percutaneous coronary intervention. investigators hypothesis is that pretreatment with unfractionated heparin in addition to aspirin at first medical contact may facilitate spontaneous reperfusion of culprit artery and procedural thrombotic complication in patients with st elevation myocardial infarction without significant risk of bleeding complications.

randomization of patients with stemi at first medical contact in a 1:1 ratio into an intervention group receiving 100 iu of unfractionated heparin (ufh) per kilogram of body weight iv and later additionally ufh after diagnostic coronary angiography according to the activated clotting time (act) and a control group receiving only ufh after diagnostic coronary angiography at the dose of 100 iu per kilogram of body weight. the primary end point of the study is timi flow at coronary angiography. secondary endpoints are: bleeding complications (defined by barc score), occurrence of cardiogenic shock, and 30-day mortality. investigators plan to randomize 600 patients.

Eligibility criteria:
inclusion criteria: * adult patients with stemi referred for primary pci * duration of symptoms less than 6 hours before presentation exclusion criteria: * pregnancy * cardiogenic shock at presentation (hemodynamic instability) * cardiac arrest before randomization * duration of symptoms for more than 6 hours before presentation

Keywords: myocardial reperfusion unfractionated heparin pre-treatment
postoperative recovery quality according to preoperative fasting time in pediatric patients undergoing nuss operation

Conditions: Pectus Excavatum

Summary: preoperative fasting is intended to lower the amount of gastric contents in order to decrease the incidence of aspiration associated with endotracheal intubation. however, recent studies show that longer fasting time does not reduce aspiration associated complications. especially in pediatric patients, long fasting time increases patients' unpleasantness and therefore increases postoperative recovery quality. it also induces hypoglycemia. in many studies, ingesting clear liquids 2 hours up to general anesthesia decreases gastric contents and therefore the incidence of aspiration pneumonia, postoperative nausea and vomiting. therefore anesthesiologist associations in the us and europe recommend to drink small amount of clear liquid (water) up to 2 hours before the surgery. nuss bar operation, or repair surgery of pectus excavatum is mostly done in pediatric patients. the procedure itself is very painful, requiring paramount amount of analgesics. use of opioid analgesics increases postoperative nausea and vomiting. in this study, our aim is to evaluate preoperative fasting time and how preoperative supplement of clear liquid affects the quality of recovery postoperatively.


Eligibility criteria:
inclusion criteria: 1. pediatric patients from age 3 to 6 2. undergoing repair surgery for pectus excavatum 3. american society of anesthesiologists class i to iii exclusion criteria: 1. any diseases or past surgical procedures involving gastrointestinal tract 2. past history of psychiatric diseases 3. on chronic analgesic medication 4. patients or patients' caregivers do not agree to attend the study
a study to evaluate the safety of inca33890 in participants with advanced or metastatic solid tumors

Conditions: Solid Tumors; Advanced Solid Tumors; Metastatic Solid Tumors

Summary: to evaluate the safety, tolerability, and dlts and determine the mtd and/or rde(s) of inca33890 in participants with select advanced or metastatic solid tumors.


Eligibility criteria:
inclusion criteria: * ≥18 years old * histologically or cytologically confirmed advanced or metastatic malignancies as defined in the protocol. * part 1: participants must have experienced disease progression after treatment with, be intolerant to, or be ineligible for, or refused available therapies, including anti-pd-(l)1 or anti-ctla4 therapy if applicable, that are known to confer clinical benefit. part 2: depending on cohort, participants may have received or not prior treatment for the malignancy under study. * ecog performance status score of 0 or 1. * willingness to undergo pre- and on-treatment tumor biopsy (core or excisional). biopsies are mandatory depending on the cohorts. * presence of measurable disease according to recist v1.1. exclusion criteria: * any known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years. * not recovered to ≤ grade 1 or baseline from residual toxicities of prior therapy. * has active autoimmune disease requiring systemic immunosuppression with corticosteroids. * brain or cns metastases untreated or that have progressed. * history of organ transplant, including allogeneic stem cell transplantation. * history of clinically significant or uncontrolled cardiac disease. * active hbv, active hcv, or hiv positive. * is on chronic systemic steroids (\> 10 mg/day of prednisone or equivalent). * chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment * participants that have been initiated on or had modifications in anticoagulation therapies within the last 3 months prior to first dose of treatment. * significant concurrent, uncontrolled medical condition, eg: * cardiovascular: participants with known vasculitis, aneurisms, and other vascular malformations of clinical significance or history of myocarditis. * gastrointestinal: any bowel obstruction within 60 days prior to c1d1. * participants with adequate laboratory values within the protocol defined ranges. other protocol-defined inclusion/exclusion criteria may apply.

Keywords: solid tumors inca33890
open vs laparoscopic pyloromyotomy for pyloric stenosis

Conditions: Pyloric Stenosis

Summary: comparison of open and laparoscopic pyloromyotomy


Eligibility criteria:
inclusion criteria: * clinical diagnosis of infantile hypertrophic pyloric stenosis exclusion criteria: * presence of co-existing congenital or chromosomal abnormality * the need to perform any additional procedure at the time of pylotomyotomy * failure to receive informed consent
regorafenib treatment patterns and survival outcomes in advanced colorectal cancer: a real-world study

Conditions: Advanced Colorectal Cancer

Summary: this is a multi-center, retrospective, real-world study. the purpose of this study is to observe the effectiveness and safety of regorafenib in chinese advanced colorectal cancer patients. the main observational goals include overall survival(os), 6 month os rate, 1 year os rate, and treatment time failure (ttf), other study goals include objective response rate( orr)、disease control rate（dcr）and adverse event(ae) of regorafenib.


Eligibility criteria:
inclusion criteria: 1. patients with colorectal cancer confirmed by pathological tissue or cytology； 2. the pathological type of colorectal tumor was adenocarcinoma； 3. patients with recurrent or metastatic, unresectable advanced colorectal cancer； 4. patients who received regorafenib at least one period treatment. exclusion criteria: 1. patients participating in other interventional clinical studies while taking regorafenib; 2. patients with other malignant tumors within 5 years before regorafenib treatment, except for cured cervical carcinoma in situ, skin squamous cell carcinoma or basal cell carcinoma, early papillary thyroid carcinoma, etc.; 3. the investigator deems that there are other factors that are not suitable for patients who participate in this study.
allo - cancer - thrombosis

Conditions: Cancer; Venous Thromboembolism

Summary: management of venous thromboembolism (vte) in patients with cancer is complex and require the intervention of many specialized health professionals, in hospital but also at home and during follow-up. the allotc project aims to integrate the management of vte within the multidisciplinary care pathway of the patient with cancer, in order to improve the management of vte in patients with cancer: optimize treatments and follow-up with appropriate anticoagulants, monitor the implementation of good clinical practice, promote patient involvement and adherence. the objective of this monocentric study is to evaluate the efficiency of the integration of the therapeutic management of vte into a specific management of patient with cancer and to set up a specialized "allotc" team that coordinates this course of care. for that purpose, the management of vte and outcome of patients with cancer and vte will be compared between two periods : traditional management and management with the "allotc" team.


Eligibility criteria:
inclusion criteria: * diagnosis of cancer or haematological malignancies * venous thromboembolism diagnosis (symptomatic or not) exclusion criteria: * life expectancy ≤ 3 months * inability to understand or sign consent * inability to read or understand the french language
study on cemented versus non-cemented hemiarthroplasty in elderly with hip fractures

Conditions: Hip Fracture

Summary: the objective is to study the overall frequency and cumulative rate (during one year) of clinical morbidity (defined as any hospitalization without fatal outcome) and mortality in all consecutive patients undergoing hf surgery (pins and prosthetic implants) and compare this to the group of patients receiving prosthetic implants and further find out if there is a difference between the non-cemented and cemented groups. between the same prosthetic groups, the investigators want to study the overall frequency of in-hospital subclinical organ damage and dysfunction of myocardium, liver and lungs, using biochemical plasma markers. finally, the investigators want to perform perioperative cost benefit calculations and out of hospital quality of life analysis between the surgical groups.


Eligibility criteria:
inclusion criteria: * patient with garden 3 or 4 fracture in acute hip fractures. * age over 75 years. exclusion criteria: * patient or relative refuse enrollment

Keywords: hip fracture hemiprosthesis bone cement clinical outcome
effectiveness of bilateral endoscopic sphenopalatine ganglion block on postoperative pain after septoplasty

Conditions: Postoperative Pain

Summary: the aim of this clinical study will investigate the efficacy of sphenopalatine ganglion block in the treatment of postoperative pain.it will also be learnt whether it reduces the consumption of analgesics in postoperative pain.the main questions it aims to answer are: will the participants' need for painkillers decrease after the operation? can sphenopalatine ganglion block be used for postoperative pain after septoplasty? the researchers will compare 2 groups with and without sphenopalatine ganglion block to see the effectiveness of sphenopalatine ganglion block. participants will: read the information participants have been given about the sphenopalatine ganglion block. in case of any side effects, please contact participant's doctor.

this randomised controlled study will be conducted in umraniye training and research hospital operating room between november 2024 and january 2025 after obtaining ethics committee and patient consent. each patient will be informed about the procedures to be performed during anaesthesia and surgery and signed informed consent will be obtained before the procedure. patients will undergo septoplasty by the same otolaryngology team. a total of 50 participants (25 envelopes each with group 1 and group 2 written inside) will be kept closed for the patients participating in the study. upon the patient's fulfilment of the conditions suitable for the study, it will be randomly determined which group he/she will be included in. thanks to this randomisation, conscious or unconscious manipulations in the selection of patients to the study group will be prevented.

Eligibility criteria:
inclusion criteria: * participants who will undergo septoplasty * 18 to 50 years old * asa score 1 or 2 exclusion criteria: * under 18 or over 50 years of age * asa score iii and above patient group * the patient is allergic to any of the drugs used * the patient has a contraindication to any of the drugs used * use of anticoagulant medication * failure of the patient to give consent * being pregnant * those with gcs retardation such as dementia, mental retardation * those with diagnosed headache

Keywords: sphenopalatine ganglion block septoplasty postoperative pain
rivaroxaban for the prevention of major cardiovascular events in coronary or peripheral artery disease

Conditions: Prevention & Control

Summary: the primary objectives of this study are: * to determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke, or cardiovascular death in subjects with coronary artery disease (cad) or peripheral artery disease (pad); * to determine whether rivaroxaban 5 mg bid compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke or cardiovascular death in subjects with cad or pad.


Eligibility criteria:
inclusion criteria: - meet criteria for cad and/or pad subjects with cad must also meet at least one of the following criteria: * age ≥65, or * age \<65 and documented atherosclerosis or revascularization involving at least 2 vascular beds, or at least 2 additional risk factors exclusion criteria: * stroke within 1 month or any history of hemorrhagic or lacunar stroke * severe heart failure with known ejection fraction \<30% or new york heart association (nyha) class iii or iv symptoms * estimated glomerular filtration rate (egfr)\<15 ml/min * need for dual antiplatelet therapy, other non-aspirin antiplatelet therapy, or oral anticoagulant therapy

Keywords: cardiovascular events rivaroxaban xarelto anticoagulant blood thinner aspirin asa coronary artery disease cad peripheral artery disease pad artery disease coronary artery bypass graft stroke heart attack angina arterial vascular disease myocardial infarction mi cardiovascular death cv death heart disease
neoadjuvant stereotactic body radiation therapy for resectable adenocarcinoma of the pancreatic head and/or body

Conditions: Pancreatic Cancer

Summary: the purpose of this study is to test the safety of focused radiation (stereotactic body radiation therapy, sbrt) on patients with pancreatic cancer that will be removed surgically.


Eligibility criteria:
inclusion criteria: * age \>18 years. * histologically confirmed pancreatic adenocarcinoma of the head and/or body; at least the majority of the histopathologic specimen must be identified as adenocarcinoma. * pancreatic tumors must be considered resectable at time of treatment planning. definition of resectable: no metastases, less than 180 degree involvement of superior mesenteric vein or portal vein, no involvement of hepatic artery, superior mesenteric artery or celiac artery * no active infection requiring hospitalization * adequate labs * life expectancy \> 3 months. * patient is to have received chemotherapy prior to enrollment. this will typically consist of 3-4 cycles of chemotherapy. patients will have a 2 week break between last chemotherapy administration and start of sbrt. exclusion criteria: * presence of metastatic disease. * infections requiring systemic antibiotic treatment.
topical allstate and nasal allergen challenge

Conditions: Allergic Rhinitis

Summary: the purpose of this study is to see whether allstate nasal spray when given in the nose is safe and can reduce the signs and symptoms of allergic rhinitis (hayfever).


Eligibility criteria:
inclusion criteria 1. males and females between 18 and 55 years of age. 2. history of grass and/or ragweed allergic rhinitis for at least 2 years. 3. positive skin test to grass and/or ragweed antigen within prior 12 months. 4. positive response to screening nasal challenge. exclusion criteria 1. respiratory disease other than allergic rhinitis, allergic conjunctivitis and mild asthma. 2. use of nasal steroids, antihistamines in the last 2 weeks. 3. upper respiratory infection, sinusitis less than 2 weeks before screening. 4. structural nasal abnormalities or nasal polyps on examination, nasal ulcer, frequent nose bleeding, recent nasal surgery or nasal trauma (within 90 days). 5. having poorly tolerated previous administration of allergens 6. nasolacrimal drainage system malfunctions. 7. participation in other investigational therapy in the last 30 days. 8. any systemic disorder or medication interfering with the study. 9. fev1\<80% of predicted at screening for subjects with mild asthma. 10. presence of allergic rhinitis symptoms in the screening period with tnss \>3 at baseline) 11. undergoing allergen desensitization therapy. 12. current smokers or recent ex-smokers. 13. not willing to give informed consent 14. inability to understand the nature and requirements of the study, or to comply with the study procedures. 15. any social or medical condition that, in the opinion of the investigator, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
comparison of neuflex and swanson metacarpophalangeal implants for rheumatoid arthritis

Conditions: Arthritis, Rheumatoid

Summary: the main hypotheses for this study are as follows: 1. the use of neuflex implant results in flexion in the fourth and fifth mp joints that is at least 10 degrees greater than with teh use of the swanson implant. 2. the use of the neuflex implant is associated with a significantly (2.5 kg or more) greater grip strength than with the use of the swanson implant.

many studies have evaluated metacarpophalangeal joint (mp) range of motion following swanson arthroplasty. these studies report that overall mp flexion is restricted postoperatively. they do not usually report individual range of motion values for each digit. therefore one cannot identify if the degree of mp flexion restriction differs by digit. we, and others, have observed that mp flexion is particularly restricted in the ring and litter finger following swanson arthroplasty. there is a new implant (neuflex), which instead of being introduced in full extension, like the swanson implant, has a resting position of 30 degrees of flexion. as mp flexion is particularly restricted in the ring and little finger, an implant that by design encourages flexion may be helpful. a need exists to establish if the use of the neuflex implant produces greater mp flexion in the ring and little finger where restricted flexion has been identified as a problem.

Eligibility criteria:
inclusion criteria: * rheumatoid arthritis * primary metacarpophalangeal arthroplasty of all 4 digits exclusion criteria: * diagnosis of other connective tissue disorder (e.g. sle, mctd) * previous surgery of mp joints * revision metacarpophalangeal arthroplasty

Keywords: metacarpophalangeal joint arthroplasty, replacement range of motion, articular randomized controlled trials swanson neuflex